 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
|||||||||
| Faculty Name and Research Interest | |
 |
Janet Amico, MD Role of oxytocin in stress, anxiety, and ingestive behaviors. |
 |
Sherrie L. Aspinall, PharmD, MSc, BCPS |
 |
Robert R. Bies, PharmD, PhD Development of heirarchical Bayesian approaches to understand nonlinearities in drug exposure and response. |
 |
Kim C. Coley, PharmD FCCP Factors that impact beneficial and adverse clinical outcomes to medications under conditions of usual care. |
 |
Billy W. Day, PhD Design, synthesis, and mechanistic (pharmacological and proteomic) evaluation of drugs and carcinogens. |
 |
Alexander Doemling, PhD |
 |
Robert B Gibbs, PhD Effects of gonadal hormones on cholinergic neurons, brain aging, and cognition. |
 |
Barry Gold, PhD Design and characterization of DNA binding molecules. |
 |
Sandra L. Kane-Gill, PharmD, MS, FCCM Evaluating the economic, clinical, and humanistic factors of drug therapy decision making for critically ill patients. |
 |
Levent Kirisci, PhD Development of instruments utilized in substance abuse; item response theory; mixed modeling; structural equation modeling. |
 |
Yong Tae Kwon, PhD Physiological functions and molecular mechanisms of ubiquitin-dependent proteolysis in mammals. |
 |
Song Li, MD, PhD Targeted delivery of functional nucleic acids. |
 |
Yong Li, PhD Structural and Functional Studies of Nuclear Receptors, Structure-Activity Relationship and Drug Discovery |
 |
Dexi Liu, PhD Gene therapy and drug delivery systems. |
 |
Scott M. Mark, PharmD, MS, Med, CHE, FASHP, FABC |
 |
Ada C. Mezzich, PhD Etiology of early onset substance abuse in high-risk children and young women. |
 |
Samuel M. Poloyac, PharmD, PhD Role of cytochrome P450 enzymes in the pathogenesis of neurotraumatic disease. |
 |
Lisa C. Rohan, PhD Design and development of drug delivery systems for STI/HIV prevention and gynecologic oncology applications. |
 |
Randall B. Smith, PhD Current research interests in community practice and educational strategies. |
 |
Ralph E. Tarter, PhD Elucidating the interaction between biobehavioral and environmental factors underlying etiology of drug abuse and addiction. |
 |
Michael Vanyukov, PhD Genetic studies of substance-use disorders, antisociality, and associated traits. |
 |
Raman Venkataramanan, PhD Drug disposition in transplant patients; regulation of drug metabolism; drug metabolism and transport during pregnancy. |
 |
Regis R. Vollmer, PhD Neural control of thermoregulation and the role of oxytocin in ingestive behavior. |
 |
Peter Wipf, PhD Total synthesis of natural products, organometallic methodology, and medicinal chemistry. |
 |
Wen Xie, MD, PhD Orphan nuclear receptor-mediated gene regulation in drug metabolism, molecular pharmacology, liver diseases, and cancer. |
 |
Xiangqun Xie, PhD, MBA GPCR NMR structural proteomics and in-silico drug design/pharmacoinformatics virtual screening method development |
 |
Jeffrey K Yao, PhD, FACB Application of metabolomics in psychosis and therapeutic monitoring. |
 |
Michael A. Zemaitis, PhD Drug metabolism and analysis of drugs and metabolites in biological fluids. |
